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Next-generation therapeutic drug development integrates 
tools from genomics, biotechnology, molecular modeling, 
and computational chemistry to reduce costs and time nec-
essary to bring new drugs to market. This redesigned drug 
development pipeline incorporates quantitative approaches 
to overcome the challenge of better, more reliable, and more 
efficient treatments. In the context of cancer and other cell-
based diseases, the ideal “perfect” drug can be envisaged as 
a compound that only affects diseased cells without harming 
the healthy surrounding cellular environment. These types of 
selective drugs are chimeric in nature, composed of a target-
ing element that discerns between undamaged and damaged 
cells, and an activity element that repairs or triggers apoptotic 
signals only in cells targeted by the targeting element. The 
most extensive family of chimeras are immunotoxins: cyto-
toxic agents comprising a modified toxin linked to a targeting 
domain derived from an antibody, a growth factor, a carbohy-
drate antigen, or a tumor-associated antigen.1 Examples of 
immunotoxins with good clinical performance are Ontak (the 
only agent approved to use for refractory cutaneous T-cell lym-
phomas by the US Food and Drug Administration),2 LMB-23 
BL22,4 and IL13-PE.5
Another family of therapeutic chimeric proteins combines 
an antiproliferative agent, such as TRAIL, with an antibody 
fragment or a natural ligand as an specific cell surface tumor 
marker:6 scFv425:sTRAIL,7 scFvCD7:sTRAIL (specific for 
CD7),8 and scFvCD19:sTRAIL (targeting CD19-positive 
cells).9 Researchers also synthetized sFasL fusion proteins 
to target the T-cell leukemia–associated antigen CD710 
or CD20.11 Type-1 interferons have also been fused with 
tumor-specific ligands, for instance, in antiCD20-interferon 
(antiCD20-IFN)12 or IFNα-2a-asparagine-glycine-arginine 
peptide13 in which the asparagine-glycine-arginine pep-
tide targets the aminopeptidase n expressed in tumor ves-
sels. IFNα-2a has also been combined with the epidermal 
growth factor (EGF) to target EGF receptors (EGFR)-over-
expressing cells.14
The sequential mechanism of action of chimeric ligands 
(Figure 1) starts by a freely diffusing chimera (Figure 1a) 
that binds via one of its subunits to its complementary 
membrane receptor (Figure 1b,c). This first binding event 
maintains the other free subunit of the chimera in the vicin-
ity of the membrane, facilitating the interaction with its cor-
responding receptor. The efficiency of the chimeric system 
depends on the balance between binding and unbinding 
rates of both ligand–receptor interactions, concentration of 
receptors for the targeting and activity elements, diffusion 
of both receptors on the membrane, and internalization of 
complexes, etc.
Herein, we present a mathematical framework to design 
and enhance synthetic chimeric ligands. As a case study, 
we apply our model to different mutants of a IFNα-2a-EGF 
chimera developed in ref. 14, in which the EGF subunit tar-
gets cells overexpressing EGFR and the IFN subunit triggers 
apoptotic signals. These chimeras induced IFNα signaling in 
an EGFR-dependent manner in HeLa, and A431 cells, as well 
as in Daudi cells engineered to overexpress EGFR into the 
Daudi cell line (300× higher than the parental cell line). The 
Daudi cell line comes from a human Burkitt lymphoma and 
is susceptible to IFNα antiproliferative activity. Antiprolifera-
tive assays comparing Daudi and Daudi-EGFR cells showed 
that the inhibition of cell proliferation by chimeric proteins 
depended on the presence of EGFR on the cell surface.
The model allows us to understand the key aspects that 
determine the selective potential of the chimera and to opti-
mize its design by testing variants with increased selectivity 
and efficiency. Our model quantitatively fits all experimental 
results, showing how different versions of the chimera exhibit 
enhanced selectivity (measured as the differential IFN activity 
of the chimera in Daudi-EGFR compared with Daudi cells). The 
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model also allows us to test the dependence of the efficiency 
of the chimera on receptor abundance, length of the linker 
between both ligand subunits, and diffusion of membrane 
receptors. This general model can be easily tailored to other 
chimeric compounds to be used as a tool to understand the 
experimental observations as well as to optimize the design of 
potential chimeric constructs with improved selectivity.
RESULTS
Activity of the chimera is enhanced in cells over­
expressing EGFR
Figure 2 compares the dynamics of the different complexes Ci 
in Daudi (Figure 2a–c) vs. Daudi-EGFR cells (Figure 2d–f). 
After ligand stimulation at t = 0, the number of complexes 
increases initially to later drop due to internalization. The 
amount of IFN ligand–receptor complexes formed decreases 
when using IFN mutants with reduced affinity. In all cases, 
the maximum amount of IFN complexes formed is higher in 
Daudi-EGFR cells (Figure 2d–f) than in Daudi cells, with 
most of the IFN complexes also bound via the EGF subunit to 
EGFR (blue line). The dynamics of the EGF and IFN recep-
tors (IFNR) is plotted in Supplementary Figure S1 online.
Given that transcription of IFN-induced genes has been 
shown to correlate to IFNR occupancy,15 the maximum activ-
ity of the chimera can be monitored in terms of the maximum 
number of IFN complexes formed. Figure 2g–j plots the 
maximum amount of IFN complexes in monomer vs. chimeric 
configurations in both cell lines. The control cell line shows no 
difference in activity between monomer and chimeric ligand 
due to its low endogenous EGFR expression (Figure 2g,h). 
On the contrary, the chimeric ligand induces higher IFN com-
plex formation in cells overexpressing EGFR, as compared 
with the monomer (Figure 2i,j). These results correlate with 
the measurements reported in ref. 14, at which the activity of 
the pathway is monitored in terms of pSTAT1 levels (a read-
out of IFN stimulation). Overall, the model shows how the effi-
ciency of chimeric ligands is achieved: the formation of the IFN 
complex is enhanced by the presence of EGFR, which binds to 
the EGF subunit of the chimera while maintaining the IFN sub-
unit close to the cell surface. This intermediate configuration 
increases the local concentration of IFN at the vicinity of the 
cell surface, facilitating the binding to IFNR. This mechanism 
increases the effective activity of IFN mutants with very low 
efficiency as monomers (K133A and R144A). With respect to 
chimeric configuration, these IFN variants outperform the wild 
type in terms of selectivity (see Selectivity is enhanced in chi-
meras with reduced IFN affinity section).
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Figure 1 Scheme of the chimeric ligand/receptor interaction. (a) 
The chimeric ligand is formed by two subunits (blue and green) 
connected by a protein linker of length “a.” Each subunit of the free 
ligand can bind to its corresponding receptor forming intermediate 
complexes (b) C1 and (c) C2. Vi is the effective reaction volume 
where the free ligand subunit is distributed (b–c) and hi corresponds 
to the height of receptor Ri (i = 1, 2) above cell surface. (d) Once 
both subunits of the ligand are bound to their corresponding 
receptors, complex C3 is formed, which gets internalized following 
the endocytotic constant    .
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Figure 2 The model predicts higher interferon (IFN) activation 
in EGFR overexpressing cells. Dynamics of formation of IFN 
complexes at L = 1 nmol/l in (a–c) Daudi and (d–f) Daudi-EGFR 
cells during 8 h. Black line corresponds to EGF complexes only 
bound via the EGF subunit (C1 variable in our model). Gray line 
corresponds to IFN complexes only bound via the IFN subunit 
(C2 variable). Blue line corresponds to complexes bound via both 
subunits of the chimera (C3 variable). (g–j) Bar diagram of the 
maximum number of IFN complexes (maximum of the sum of blue 
and gray lines in a–f) for monomer and chimeric ligands in ref. 14 
(g–h) Daudi and (i–j) Daudi-EGFR cells. EGF, epidermal growth 
factor; EGFR, epidermal growth factor receptor; WT, wild-type.
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Selectivity is enhanced in chimeras with reduced IFN 
affinity
The efficacy of drugs in triggering apoptotic responses is often 
characterized in terms of percentage of viable cells in a popu-
lation after treatment, in the form of dose–response curves.14 
To correlate the model predictions with the experimental dose–
response curves in ref. 14, we perform a calibration using val-
ues for the wild-type IFN monomer in both cell lines tested 
(see Methods section). This calibration translates the maxi-
mum number of IFN complexes formed into percentage of via-
ble cells, and is used to calculate theoretical dose–response 
curves for the rest of monomer mutants and chimeric con-
structs, to be compared with their corresponding experimen-
tal curves. Other measurements of the chimeric activity, such 
as the sum of the number of IFN complexes formed until the 
maximum is reached, have also shown good correlation with 
experimental data (see Supplementary Figure S2 online).
Figure 3 shows the dose–response curves calculated for 
the two cell lines and the three different IFN mutants in mono-
meric and chimeric configurations. In Daudi cells  (Figure 
3a,c,e) the difference between chimera and monomer is 
negligible for all mutants. On the other hand, Daudi-EGFR 
cells (Figure 3b,d,f) present stronger response to chimeric 
ligand vs. monomer for all three IFN mutants. This difference 
increases when using mutants with reduced IFN affinity, 
resulting in a wider range of concentrations at which the 
monomer has a minimal effect whereas the chimera shows a 
strong effect in terms of percentage of viable cells.
Figure 3g–j plots the half maximal effective concentra-
tion (EC50) values of the ligand predicted by the model and 
the experimental data for each chimera in Daudi and Daudi-
EGFR cells in ref. 14. The EC50 of the monomer (Figure 3g,h) 
increases as the affinity of the IFN mutants decreases, i.e., 
progressively higher ligand concentrations are required to trig-
ger apoptosis in 50% of the cells. Of note, each IFN monomer 
mutant exhibits a higher EC50 in Daudi-EGFR cells as com-
pared with the parental Daudi cell line, evidencing higher resis-
tance of Daudi-EGFR cells to treatment with the IFN monomer. 
We hypothesize that this higher resistance is caused by the 
proliferative activity derived from EGFR overexpression.
EC50 values for the different chimeras are equivalent to 
their corresponding monomers when applied to Daudi cells, 
as expected (Figure 3g,i). On the contrary, EC50 values are 
lower for all chimeric mutants in Daudi-EGFR cells (compare 
Figure 3i with Figure 3j), meaning that low concentrations of 
the chimera can trigger stronger effect on these cells than on 
Daudi cells. This difference determines the selective power of 
chimeric constructs when applied to a population of cells, and 
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Figure 3 Theoretical dose–response curves predict highest selectivity for lowest affinity interferon mutants. Dose–response curves to 
compare cytotoxicity of the monomeric (green dotted lines) and chimeric (blue dotted lines) proteins in (a,c,e) Daudi and (b,d,f) Daudi-
EGFR cell lines. (g–j) Bar diagram representing experimental and theoretical half maximal effective concentration (EC50) values for (g–h) 
monomer and (i–j) chimeric ligands (see Methods section). Numbers above each bar correspond to the EC50 (nmol/l) values for each 
condition. Note the different scale in the y-axis. EGFR, epidermal growth factor; WT, wild type.
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when the activity element induces a stronger response in cells 
overexpressing the receptor of the targeting element. When 
overexpression of this receptor is a marker of disease, these 
chimeric constructs can trigger cytotoxic activity in unhealthy 
cells, leaving healthy cells unharmed. Therefore, comparison 
between Figure 3i,j shows that the mutant with the lowest IFN 
affinity (R144A) presents the highest selectivity, having a strong 
effect on unhealthy Daudi-EGFR cells whereas leaving healthy 
cells undamaged for a wide range of ligand concentrations.
Overall, the model quantitatively reproduces the experi-
mental data for different monomers and chimeric constructs,14 
and shows that the most selective chimera is the mutant 
with reduced affinity toward IFNR, again, consistent with the 
experiments.
Efficiency of the chimera depends on the balance 
between EGFR and IFNR expression
In the previous section, the model illustrates how the selectiv-
ity of chimeric constructs is achieved between cells expressing 
low and high levels of the targeting element receptor. However, 
in vivo cells do not express a disease marker in an on/off fash-
ion but in a wide range of expression levels.16 To understand 
how the expression level of receptors inﬂuences the efficiency 
of the chimera, we calculate the maximum number of IFN 
complexes formed for different values of initial EGF and IFNR 
after stimulation with 1 nmol/l of chimeric ligand. Results are 
represented in Figure 4, in which each point in the graph cor-
responds to the maximum number of IFN complexes formed 
at certain values of IFNR and EGFR. Blue color represents 
harmless levels of IFN complex formed and red represents 
IFN complex levels high enough to trigger apoptosis in all 
cells of a population. IFNR and EGFR expression levels for 
Daudi (white circle) and Daudi-EGFR (white asterisk), in our 
experimental model system, are marked in all panels.
For a constant ligand concentration, wild-type chimera activ-
ity (Figure 4a) does not depend on EGFR expression levels, 
respectively. This means that upon crossing a certain threshold 
in IFNR levels, all cells will die independently of the expression 
WT chimera
* * *5
3
N
um
be
r o
f E
G
F 
re
ce
pt
or
s
1
0
1 3
Number of IFN receptors
5
×103
×103 1 3
Number of IFN receptors
5 ×103 1 3
700
500
300
100
Number of IFN receptors
5 ×103
K133A chimera R144A chimera
a b c
Figure 4 Chimeric ligand activity depending on the number of EGF 
and interferon (IFN) receptor expression. Activity of the chimera 
measured as the maximum number of total IFN complexes, C2 + 
C3, in a color map as a function of initial amount of EGF and IFN 
receptors on the cell membrane. We varied the parameters R1 (0) 
and R2 (0) in Table 1 from 1 to 6,000 number of molecules. Ligand 
concentration L = 1 nmol/l. Color threshold has been selected to 
mark in red the number of IFN complexes that kills all the cells 
(0% cell viability). White symbols represent experimental values of 
EGF and IFN number receptors for Daudi (o) and Daudi-EGFR (*) 
cells, respectively. EGF, epidermal growth factor; EGFR, epidermal 
growth factor receptor; WT, wild-type.
2
Diffussion limited
* * *
Diffussion limited
Reaction limited Reaction limited
Lo
g 1
0 
(D
) c
m2
/s
−9.2
−10
−10.8
12
a (Number of segments)
20 2 12
a (Number of segments)
20 2 12
a (Number of segments)
20
800
1,200
1,600
WT chimera K133A chimera R144A chimera
a b c
Figure 5 Chimeric ligand selectivity depends on receptor diffusion 
and linker length. Differential activity between Daudi and Daudi-EGFR 
cell lines (in a color code) as a function of receptor diffusion coefficient 
(D) and linker length (number of linker subunits) for the chimeras 
containing the (a) wild type, (b) K133A, and (c) R144A IFN ligands. 
The parameters corresponding to the experimental construct14 
are marked with a black asterisk. White line represents maximum 
selectivity as a function of linker length for each value of the diffusion 
coefficient. The range in D where a maximum is observed separate 
the reaction limited regime (selectivity decreases as a function of linker 
length) from the diffusion limited regime (selectivity slightly increases 
as a function of linker length). Ligand concentration for each mutant is 
chosen at the half maximal effective concentration value of activity for 
the Daudi-EGFR cell line. EGFR, epidermal growth factor receptor.
Table 1 Kinetic parameters used in the chimeric model
Parameter Value Ref.
koff1
0.24 min−1 30
kon1
0.09 nmol/l−1 min−1 30
ke1
0.15 min−1 31
h1 90 Å 32,33
D1 2–2.4 × 10−10 cm2/s 34
koff2  WT
0.66 min−1 29
kon2  WT
0.22 nmol/l−1 min−1 29
ke2  WT
0.046 min−1 28
koff2  K133A
1.08 min−1 29
kon2  K133A
0.041 nmol/l−1 min−1 29
ke2  K133A
0.046 min−1 28
koff2  R144A
2.58 min−1 29
kon2  R144A
0.021 nmol/l−1 min−1 29
ke2  R144A
0.046 min−1 28
h2 50 Å 35
D2 10−10 cm2/s 21
A 900 μm2 23
a 48.5x10−4 μm 14
R1(0) Daudi cells 22 molecules 14
R2(0) Daudi cells 2,800 molecules 14
R1(0) Daudi-EGFR cells 5,640 molecules 14
R2(0) Daudi-EGFR cells 3,600 molecules 14
C1(0) = C2(0) = C3(0) 0 molecules
Parameter values of EGF and IFN binding, unbinding, and endocytotic 
rates for a quantitative analysis of our system, corresponding to EGF-
EGFR wild-type system and IFN-IFNR wild-type and mutants of IFN, 
from recent publications. EGF, epidermal growth factor; EGFR, epidermal 
growth factor receptor; IFNR, interferon receptor.
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levels of our disease marker, EGFR. On the other hand, the 
R144A mutant chimera (Figure 4c) shows low activity in cells 
with low numbers of EGFR, but also reduced efficiency in cells 
with intermediate levels of EGFR expression, with the result that 
potentially harmful cells can be left undamaged. The mutant 
with intermediate affinity, K133A (Figure 4b), exhibits the best 
trade-off between selectivity and efficiency, with strong activ-
ity in cells expressing high and intermediate levels of EGFR 
(disease cells) and low activity in cells expressing low levels of 
EGFR (healthy cells).
Taken together, these results show that the expression lev-
els of both targeting and activity receptor elements modulate 
the efficiency and selectivity of the chimera, and that different 
versions of the chimera can be designed and optimized in 
specific situations to achieve the best compromise between 
selective killing and efficiency.
Selectivity of the chimera depends on linker length and 
receptor diffusion
As discussed in the Methods section, formation of C3 complex 
via Eqs. 4 and 5 depends on two factors: first, both receptor 
types must become close enough on the cell surface. This pro-
cess is controlled by diffusion and favored by longer chimera 
linkers a (see Eq. 7). In addition, the effective affinity constant 
k ion′  (Eq. 9) decreases with linker length because the effec-
tive reaction volume increases for longer linkers. The global 
coupling rate kci  in Eq. 6 is dominated by the slowest process: 
if diffusion of receptors is slow k kci i~ diff, and the reaction is 
said to be diffusion limited. On the other hand, for fast diffusive 
transport, k kci i~ on′, and the process becomes reaction limited. 
Between both regimes, there could be an intermediate optimal 
linker that maximizes the activity.
In ref. 14, the linker is formed by a chain of seven identical 
subunits of Gly4-Ser residues. The linker length a is estimated 
as the average end-to-end distance of a protein polymer con-
taining n Kuhn segments (the Gly4-Ser subunits), using a 
worm-like chain model:17
(1)
where N is the number of subunits, l
c
 = N·aK and lp = aK/2 are 
the contour and persistent lengths, respectively. The Kuhn 
segment length, aK, is calculated as aK = 5·Cd, where Cd = 3.8 Å is the length of a residue.
To study the impact of receptor diffusion and linker length 
on the selectivity of chimeras, we calculated the difference in 
activity (measured as the maximum number of IFN complexes 
formed) between Daudi and Daudi-EGFR cells varying system-
atically the diffusion coefficient and the number of linker sub-
units.  Figure 5 plots this differential activity in a color code as a 
function of linker length across a physiologically relevant range 
of diffusion coefficients for receptors in the membrane (D ∈ 
10–11–10–9 cm2/s). Calculations corresponding to the experimen-
tal values are marked as asterisks. White lines mark a shallow 
maximum in differential activity as a function of linker length. For 
the wild-type chimera (Figure 5a), C3 formation is mainly diffu-
sion limited, because the differential activity slightly increases 
with the linker length. For the K133A and R144A mutants 
 (Figure 5b,c) the selectivity increases as expected, and C3 for-
mation is mainly reaction limited, meaning that shorter linkers 
enhance the selective potential of the chimera. This presents a 
practical advantage because shorter linkers are easier to syn-
thesize and longer chimeras are prone to cleavage in vivo.
DISCUSSION
In this article, we present a theoretical model for chimeric 
ligands that allows us to study and optimize the selectivity of 
these types of constructs toward specific cell types. Some of 
these synthetic compounds have been developed as selective 
drugs,1,6,7,10,12 allowing high activity at very low drug concentra-
tion and therefore, reducing side effects. Our model provides an 
in silico tool to design and test the efficiency of new synthetic 
compounds, as well as to optimize the existing ones by testing 
variants with improved selective potential.
When tailored to the specific case of IFN-EGF chimera 
using parameter values from ref. 14, our model quantitatively 
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Figure 6 Calibration curves for the IFN wild-type monomer in Daudi-
EGFR and Daudi cell lines. (a,b) Model prediction of maximum IFNR 
activation for different ligand concentrations. (c,d) Experimental 
dose–response curves from ref. 14 fitted as sigmoidal curves. 
(e,f) Calibration curves to correlate predicted IFNR activation with 
experimental cytotoxic activity for a given ligand concentration. 
Parameters for the sigmoidal fitting of the calibration curves: (e) for 
Daudi cells are maximum value (E
max
) =100, minimum value (E0) = 
0, Inﬂection Point (IP) = 160.9, Slope (S) = −3.3 and (f) for Daudi-
EGFR cells are E
max
 = 100, E0 = 0, IP = 814, S = −3.4. Sigmoidal 
fitting perfomed using an in-house MATLAB script. EGFR, epidermal 
growth factor receptor; IFN, interferon; IFNR, interferon receptor.
CPT: Pharmacometrics & Systems Pharmacology
Rational Design of Chimeric Ligands in Selective Drug Therapies 
Doldán-Martelli et al
6
reproduces the experimental results of the different chimeric 
constructs in terms of pathway activation (Figure 2g–j) and 
cytotoxic potential (Figure 3g–j).
We restricted our model to interactions occurring at the 
membrane level, calibrating downstream events using the 
experimental dose–response curve for the WT-IFN monomer 
(see Methods section). A detailed mathematical implementa-
tion of all downstream molecular interactions that ultimately 
trigger cytotoxic response will reduce the generality and sim-
plicity of our model, so we consider this approach far from the 
scope of this contribution. In addition, internalization of C3 is 
computed as the sum of the internalization constants of both 
C1 and C2 complexes, assuming they are independent. How-
ever, the proximity of both complexes when in C3 configuration 
may induce dependence on the internalization of proximal 
active receptors linked to the same chimeric molecule.
Membrane diffusion of receptors and complexes is assumed 
uniform, so the well-known heterogeneity of the plasma mem-
brane can impact diffusion of the components on the mem-
brane. Moreover, the dimeric nature of both EGF and IFN 
complexes18,19 is not considered for the sake of generality. 
Instead, a simpler 1:1 ligand–receptor interaction scheme is 
considered. Given the accuracy of the 1:1 model reproducing 
the experimental results (Figure 3g–j), we hypothesize that 
receptor homodimerization is not playing a significant role in 
the dynamics of the system. In addition, the model does not 
include synthesis and degradation of free receptors, assum-
ing a dynamic equilibrium that keeps a constant concentra-
tion of free receptors in unstimulated conditions.
The model also assumes that both subunits of the chime-
ric ligand are bound to receptors of the same cell. However, it 
is known that chimeras can act in a paracrine manner, cross-
linking receptors of nearby cells.7 Finally, as previous studies 
suggested, EGF may have prosurvival signals, which are not 
considered in our model, and would counteract the cytotoxic 
activity of IFN.20 A detailed model including the effect of EGF 
stimulation on cell proliferation at cell population level is in 
progress.
Despite all simplifications and assumptions, the model 
accurately reproduces the experimental data14 for all com-
pounds and both cell lines tested in a quantitative fashion. 
The present model provides a reliable and systematic tool 
to design chimeric ligands, allowing us to determine optimal 
configurations before synthesis and in vivo tests. All experi-
mental data used here correspond to the IFN-EGF specific 
scenario, but the generality of the model ensures a straight-
forward customization to model other chimeric designs, 
using different combinations of activity and targeting ele-
ments to design selective compounds against specific cell 
types.
METHODS
The chimeric ligand–receptor system can be considered as 
an extension of the monovalent ligand–receptor interaction 
model,21 assuming a sequential process with a single ligand 
able to interact with two different receptors following the 
scheme:
(2)R L Ck
k
kon
off
e
1 1
1
1
1
+  → ∅ 
 
(3)
(4)
(5)
Eqs. 2 and 3 correspond to the individual binding of each sub-
unit of the chimeric ligand L to its complementary receptor Ri to 
produce intermediate complexes Ci, where i = 1, 2 corresponds 
to each of the two targeted species (Figure 1b,c). These inter-
mediate complexes are formed by one ligand subunit linked to 
its corresponding receptor whereas the other subunit is free and 
available to interact with its receptor via Eqs. 4 and 5 to gener-
ate the complex C3 (Figure 1d). This second binding event is 
modulated by two factors: the two-dimensional diffusion of the 
receptors at the cell membrane and the increase in local con-
centration close to the cell membrane due to the first binding 
event.22 The coupling rate constant ( kci ) is calculated as:21
(6)
The diffusive rate constant, k idiff, is calculated using the 
model for binding of cell surface molecules to receptors from 
ref. 21, where the intermediate complexes C1 and C2 are con-
sidered as numbers of membrane molecules:
(7)
Here D = D1 + D2 is the sum of diffusion coefficients on the 
cell membrane for both receptor species, and A is the typi-
cal cell surface area for mammalian cells.23 The parameter bi 
represents the average half-distance between receptors Ri 
on the cell surface, and is estimated as:
(8)
The parameter a corresponds to the linker length between 
ligand subunits (Eq. 1). Normalization of k idiff  by cell surface 
area A, Eq. 7, is necessary to express the diffusive rate con-
stant in # molecules−1 min−1, the same units as k ion′  below. 
We remark that all molecular species, Ri, Ci, are given in mol-
ecule numbers.
On the other hand, k ion′  is the effective affinity constant 
recalculated for a two-dimensional binding process21 as 
follows:
(9)
where k ion  is the corresponding three-dimensional rate affin-
ity constant in Eqs. 2 and 3, N
av
 is Avogadro’s number, and 
Vi is the effective reaction volume for the second binding 
event assumed as a spherical gasket above the cell surface 
where the free subunit gets distributed after the first binding 
event (see Figure 1b,c). This volume is calculated as Vi = 
A·(hi + a), where hi is the height of the extracellular domain 
of the receptor. Finally, the uncoupling rate kui  in Eqs. 4 and 
5 can be written as:
(10)
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Where γ i i i ik k k≡ on diff on′ ′+( )  the “capture probability” factor 
for receptor Ri, quantifying the probability that closely associ-
ated Ri and Cj (i, j = 1, 2) bind to become a C3 complex.21 ke 
represents the internalization constant of each of the differ-
ent complexes after ligand binding, assuming k k ke e e3 1 2= + , 
because internalization of the two complexes in C3 is consid-
ered to be independent. The set of reactions 2–5 is translated 
into the following differential equations:
(11)
(12)
(13)
(14)
(15)
Note that, in contrast to other models of signal transduction 
by receptors,24 we consider extracellular ligand concentra-
tion as a constant in our equations. This choice is justified in 
 Supplementary Text S1 online. To solve Eqs. 11–15 numeri-
cally, we developed an in-house MATLAB (MathWorks, Natick, 
MA) script (data not shown) using parameters for the chimeric 
system described.14 The system is composed by EGF as tar-
geting element linked to different mutants of the IFNα-2a as the 
activity element. The activity of the chimera corresponds to the 
cytotoxic effect of the IFNα-2a subunit. This chimeric design is 
assumed to guide the antiproliferative and apoptotic effect25,26 of 
interferon toward cells overexpressing EGFR (upregulated in a 
number of tumoral cell lines).27 Mutants of IFN exhibiting different 
affinity toward the IFNR were tested in Daudi cells engineered 
to overexpress EGFR cells (~300× the levels of the Daudi con-
trol cell line). For our study, we selected the wild-type form of 
IFNα-2a and the mutant variants, K133A and R144A,28,29 with 
progressively less avidity toward IFNR. Parameter values are 
taken from experimental studies28–35 and are listed in Table 1. 
Within our modeling scheme, variable R1 represents EGFR, R2, 
IFNR, C1 and C2 represent EGF and IFN complexes alone (i.e., 
complexes formed by the receptor and one end of the chimera, 
with the other chimera subunit free to bind to its corresponding 
receptor). C3 corresponds to the chimera linked to EGFR and 
IFN at the same time. The initial number of EGFR and IFNR is 
written as R1 (0) and R2 (0), and the initial amount of complexes 
C1, C2, and C3 is equal to 0 (see Table 1).
To compare the theoretical predictions with experimental 
measurements, we established a correlation between cytotoxic 
effect of IFN and number of IFN complexes predicted. To do so, 
we compute the maximum value of IFN ligand–receptor com-
plexes (i.e., C2 +C3 in the model) for the range of ligand concen-
trations experimentally used, resulting in the sigmoidal curves 
in Figure 6a,b. The prediction of maximum IFN complexes for 
each ligand concentration is correlated with its cytotoxic effect 
using the experimental dose–response curves for the wild-type 
IFN monomer ligand in ref. 14 for Daudi and Daudi-EGFR cells 
(both are sigmoidal curves reinterpreted in Figure 6c,d). The 
resulting calibration curves for both cell types are shown in 
Figure 6e,f, correlating the number of IFN complexes predicted 
with its activity in terms of percentage of viable cells. The cali-
bration curve is then used to calculate the predicted cytotoxicity 
for other mutants of IFN monomer and all chimeric variants.
Supplementary Figure S2 online plots the dose–response 
curves and EC50 values calculating the IFN activity as the sum 
of the number of IFN complexes formed before the maximum 
(to be compared with Figure 3, calculated using the maximum 
value of IFN complexes). Both methods produce equivalent 
results in complete agreement with the experimental data.
The quantitative fit of the EC50 values for the different IFN 
monomers with the experimental data provides a good vali-
dation of the model, because changes in the affinity of the 
IFN ligand fully correlate with the experimental phenotype.
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WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
✓  Chimeric ligands achieved their selective potential 
by taking advantage of the differential expression 
of disease markers targeted by one subunit of the 
chimera, whereas the other subunit triggers repairing 
or cytotoxic responses.
WHAT qUESTION DID THIS STUDy ADDRESS?
✓  In this study, we present a mathematical model that 
allows in silico design and optimization of chimeric 
constructs in terms of their selectivity and efficiency.
WHAT THIS STUDy ADDS TO OUR KNOWLEDGE
✓  To our knowledge, our study provides the first math-
ematical framework that focuses on chimeric drugs, 
allowing us to understand the results of chimeras al-
ready tested experimentally, as well as to investigate 
new designs with improved selective potential.
HOW THIS MIGHT CHANGE CLINICAL 
 PHARMACOLOGy AND THERAPEUTICS
✓  Our model constitutes a step forward toward a more 
systematic and reliable design of selective chimeric 
compounds before their in vivo implementation.
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